Microbix Advances Modernized Manufacturing for Kinlytic Clot-Buster Drug

Microbix Biosystms ( (TSE:MBX) ) just unveiled an announcement.

Microbix Biosystems and its U.S. commercialization partner Sequel Pharma have advanced the redevelopment of Kinlytic urokinase, a biologic drug used to dissolve blood clots, by modernizing the manufacturing process for its active ingredient. The contracted CDMO has updated cell culture methods to reduce or eliminate products of animal origin, aligning with current safety best practices and paving the way toward a supplemental biologics license application to reintroduce Kinlytic, initially for clearing clots in indwelling venous catheters in the U.S. market.

The Kinlytic program is now moving into formulation, fill, and finish drug product phases, with Microbix’s scientific team supporting this technically challenging work alongside Sequel and the CDMO. Management highlights that the completion of the updated drug substance process represents the clearing of key technical hurdles on the path to reapproval and broader clinical use, and the company plans to provide future updates as it reaches further manufacturing, clinical, regulatory, and commercial milestones for the product’s return to global markets.

The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.22 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.

Spark’s Take on TSE:MBX Stock

According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.

The score is held down primarily by weakened financial performance (return to losses and negative cash flow) and only mildly supportive technicals (negative MACD and below longer-term averages). The earnings call adds some offset from improving sequential trends, cash collections, and operational initiatives, but near-term revenue/margin uncertainty—especially tied to China—keeps the overall score below average.

To see Spark’s full report on TSE:MBX stock, click here.

More about Microbix Biosystms

Microbix Biosystems Inc. is a Canadian life sciences company that develops and manufactures proprietary biological products for human health, including critical ingredients and devices for the global diagnostics industry. Its portfolio spans immunoassay antigens, laboratory quality assessment products (QAPs), and QUANTDx reference materials, which support clinical lab proficiency testing, assay development, and diagnostic workflow quality, and are sold in over 30 countries through a global distributor network.

The company also leverages its biological expertise to develop other proprietary technologies, notably Kinlytic urokinase, a biologic thrombolytic drug for treating blood clots, and reagents such as DxTM for patient-sample collection, underpinned by multiple international quality accreditations and regulatory registrations. Microbix is publicly traded on the TSX and OTCQX and is headquartered in Mississauga, Ontario, where it employs over 120 staff and generates multimillion-dollar annual revenues from its diversified product base.

Average Trading Volume: 65,459

Technical Sentiment Signal: Sell

Current Market Cap: C$31.87M

See more data about MBX stock on TipRanks’ Stock Analysis page.